Q2 2025 BioArctic AB Earnings Call Transcript
Key Points
- BioArctic AB (BRCTF) reported a strong quarter with increasing royalties from Leqembi, indicating profitable growth.
- The company has entered a new partnership with Novartis, utilizing its Brain Transporter technology, marking its third such collaboration.
- Leqembi has been approved in nearly 50 countries, with recent launches in Europe, including Austria and Germany.
- BioArctic's financials are robust, with record royalties and a significant upfront payment from Novartis, contributing to a strong cash position.
- The company's R&D portfolio is expanding, with exidavnemab progressing well in Phase 2a trials and receiving orphan designation in the US and EU for MSA.
- There is a potential for lower sales in China in the coming quarters due to a one-time stocking effect in Q2.
- The European launch of Leqembi is expected to take time, with gradual rollouts and potential infrastructure challenges similar to those faced in the US.
- BioArctic's operating expenses have increased significantly, partly due to currency effects and heavy R&D spending.
- The profitability for the second half of the year is expected to be lower than the first half, despite strong financial performance.
- The timeline for the evaluation of the Novartis collaboration is approximately two years, indicating a delay before potential revenue realization from this partnership.
Thank you. Good morning, and welcome to BioArctic's presentation for the second-quarter of 2025. BioArctic is now entering a new era. It's an era of profitable growth. And I think it's signified by yet another strong quarter and a lot of activities throughout the different parts of the business.
We see increasing Leqembi royalties, and we are very pleased with the new partnership with Novartis. It's the third partnership utilizing our Brain Transporter technology and it's the first of its kind. And I'll talk more about that in today's presentation. Next slide, please. BioArctic is listed at Nasdaq Stockholm Large Cap, and this is our disclaimer.
Next slide, please.
I'm Gunilla Osswald, and I'm the CEO of BioArctic. And today, I will share the presentation with our CFO, Anna-Kaija Gronblad; and also with our Chief R&D Officer, Johanna Fälting; and our Chief Commercial Officer, Anna-Kaija Gronblad.
Next slide, please. I will start our presentation, and I will be giving some key highlights. Next
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
